Condition
Immune Effector Cell Associated Neurotoxicity Syndrome
Total Trials
6
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 6 trials
Late-Stage Pipeline
17%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
5Total
Not Applicable (2)
P 1 (1)
P 2 (1)
P 4 (1)
Trial Status
Recruiting3
Not Yet Recruiting2
Withdrawn1
Clinical Trials (6)
Showing 6 of 6 trials
NCT07403812Not ApplicableNot Yet Recruiting
Assessing DCog Short for Neurotoxicity in CAR-T
NCT07390071Not ApplicableRecruiting
Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
NCT06706102Phase 4RecruitingPrimary
Temporal Characterization of Extracellular Vesicles During Cellular Therapy Using CAR-T Cells and During the Occurrence of Immune Effector Cell-Associated Neurotoxicity Syndrome
NCT06703216Phase 1Not Yet Recruiting
Pre-emptive Anakinra for Cytokine Event Reduction
NCT06352866Phase 2Withdrawn
Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM
NCT05643092RecruitingPrimary
Biomarker and Imaging Package Study in Immune Effector Cell-Associated Neurotoxicity Syndrome
Showing all 6 trials